Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

NCT06905288

Status	RECRUITING
Sponsor	Novartis Pharmaceuticals
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (7)

- Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
- Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of e 4
- Subjects who have never used TNFi, JAKi, or IL-17i drugs before
- Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
- Subjects who have a time of less than 5 years since AS diagnosis

... and 2 more (see full listing online)

Exclusion (4)

- Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
- Subjects who have congenital/traumatic spinal deformities
- Subjects currently enrolled in other clinical studies
- Subjects who have any contraindications to secukinumab treatment

Locations (2 total)

Novartis Investigative Site, Jinju, Gyeongsangnam-do, South Korea
Novartis Investigative Site, Busan, South Korea